Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., operating as Kelun-Biotech, is a biopharmaceutical company dedicated to the research and development, manufacturing, commercialization, and global collaboration of innovative biological and small molecule drugs. Established in 2016, the company's mission is to address significant unmet medical needs in China and worldwide, with a strategic focus on major disease areas such as oncology, autoimmune disorders, and metabolic diseases. Its headquarters are located in Chengdu, Sichuan, China.

Kelun-Biotech is a pioneer in the development of Antibody-Drug Conjugates (ADCs) and novel Drug Conjugates (DCs), having established its proprietary OptiDC™ platform. The company's product portfolio includes two marketed ADC drugs: sacituzumab tirumotecan (sac-TMT), approved for indications such as triple-negative breast cancer and EGFR-mutated non-small cell lung cancer, and trastuzumab botidotin, approved for HER2-positive breast cancer. Beyond ADCs, its pipeline features over 30 innovative drug projects, with several in clinical stages, including Tagitanlimab (a PD-L1 mAb), Cetuximab N01 (an EGFR mAb), A400 (a RET inhibitor), and A296 (a STING agonist).

In recent developments, Kelun-Biotech's ITGB6-targeted ADC, SKB105, received Investigational New Drug (IND) approval for advanced solid tumors in January 2026. Additionally, sac-TMT in combination with pembrolizumab was granted Breakthrough Therapy Designation for the first-line treatment of PD-L1 positive non-small cell lung cancer. Led by Executive Director, President, and CEO Dr. Ge Junyou, Kelun-Biotech has positioned itself as a leader in China's innovative drug sector, actively expanding its global presence through strategic partnerships with companies like MSD, Ellipses, Windward Bio, and Crescent Biopharma. The company was successfully listed on the Hong Kong Stock Exchange in July 2023.